Current and Emerging Treatment Options for Multiple Myeloma – Live

Description

Program Description

---

Click to Go to the Event Registration

Multiple myeloma (MM) is a plasma cell neoplasm. In the current era of new agents, such as immunomodulatory drugs and proteasome inhibitors, and antibodies, enormous progress has been achieved in the therapy of MM. There are now sensitive screening methods for the diagnosis of MM. Accurate diagnosis is based on several factors, including physical evaluation, patient history, symptoms, and diagnostic testing results. The standards for initial diagnostic tests are determined by blood and urine tests, bone marrow biopsy, and skeletal imaging, such as X-rays, CT scans, and MRI scans. Major and minor criteria are required to confirm the diagnosis of multiple myeloma and help to determine the classification and staging of MM and whether it is smoldering myeloma (asymptomatic), symptomatic myeloma, or a monoclonal gammopathy of undetermined significance (MGUS). Multiple myeloma treatment options have increased significantly over the last ten years. The standard MM treatment consists of high-dose chemotherapy combined with autologous stem cell transplantation (ASCT). Several factors may determine MM treatment, such as age and general health, results of laboratory and cytogenetic (genomic) tests, and symptoms and disease complications. Conventional treatment options must be evaluated for older patients (> 70 – 75 years) who are not eligible for high-dose chemotherapy and ASCT due to their age and/or severe comorbidities. It is essential to include supportive therapy in the integral treatment concept, to control pain or retain function or mobility. Pivotal studies evaluated the cytogenetic classification, staging, and risk stratification and novel treatment approach with protease inhibitors (carfilzomib, ixazomib, bortezomib); monoclonal antibodies (datatuzumab, elotuzumab, isatuximab); immunomodulatory agent (lenalidomide), histone deacetylase inhibitors (panobinostat, vorinostat), doublet and triplet combination therapies in patients with newly diagnosed and relapsed/refractory MM; and the evolving role of bb2121 anti-BCMA CAR T-Cell therapies for MM.

Agenda

---

• Clinical Vignette 1 (Pretest – Audience Response System)
• Update on multiple myeloma (MM) disease definitions and diagnostic criteria based on IMWG guidelines
• Updates in frontline therapy for MM
• Clinical Vignette 1 (Posttest – Audience Response System)
• Clinical Vignette 2 (Pretest – Audience Response System)
• An approach to consolidation and maintenance therapy for MM
• Selecting and sequencing therapies in relapsed MM
• Clinical Vignette 2 (Posttest – Audience Response System)
• Clinical Vignette 3 (Pretest – Audience Response System)
• BCMA as a therapeutic target and advantages of CAR)-modified T-cell therapy for MM
• Therapeutic potential of bispecific antibodies and antibody-drug conjugates in the treatment of patients with MM
• Clinical Vignette 3 (Posttest – Audience Response System)
• Questions from participants and panel discussion

Intended Audience

---

Hematologists/oncologists, nurse practitioners, physician assistants, and nurses.

Commercial Supporter

---

This activity is supported by educational funding provided by Amgen.